Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review
Open Access
- 6 February 2018
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 41 (5), 489-509
- https://doi.org/10.1007/s40264-017-0636-9
Abstract
Interleukin-13 and interleukin-4 are type-II cytokines signalling through the shared type II interleukin-4 receptor. As a result of their structural similarity, interleukin-13 and interleukin-4 have overlapping functions in the mediation of type-II-driven diseases and are, therefore, promising targets of biologic drugs currently in development for the treatment of such diseases, including asthma and atopic dermatitis.Funding Information
- AstraZeneca, Cambridge, UK
This publication has 82 references indexed in Scilit:
- Reduced type II interleukin-4 receptor signalling drives initiation, but not progression, of colorectal carcinogenesis: evidence from transgenic mouse models and human case–control epidemiological observationsCarcinogenesis: Integrative Cancer Research, 2013
- Interleukin‐13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotypeEMBO Molecular Medicine, 2012
- Preclinical development of CAT‐354, an IL‐13 neutralizing antibody, for the treatment of severe uncontrolled asthmaBritish Journal of Pharmacology, 2011
- Silencing IL-13Rα2 Promotes Glioblastoma Cell Death via Endogenous SignalingMolecular Cancer Therapeutics, 2011
- Transcriptional regulation by STAT6Immunologic Research, 2011
- An open‐label, single‐dose bioavailability study of the pharmacokinetics of CAT‐354 after subcutaneous and intravenous administration in healthy malesBritish Journal of Clinical Pharmacology, 2010
- Epithelial interleukin-4 receptor expression promotes colon tumor growthCarcinogenesis: Integrative Cancer Research, 2010
- Molecular and Structural Basis of Cytokine Receptor Pleiotropy in the Interleukin-4/13 SystemCell, 2008
- Safety of anti‐immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infectionClinical and Experimental Allergy, 2007
- lnterleukin-13 is a new human lymphokine regulating inflammatory and immune responsesNature, 1993